May 27, 2025
Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH
May 22, 2025
Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
May 13, 2025
Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models
May 06, 2025
Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models
Apr 17, 2025
Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers
Apr 15, 2025
Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor
Apr 10, 2025
Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor
Apr 02, 2025
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024
Mar 20, 2025
Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy
Sep 25, 2024
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
Sep 19, 2024
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases
Mar 15, 2024
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
Jan 26, 2021
Galmed Pharmaceuticals Announces Upcoming Publication in JHEP Reports of New Data Supporting Aramchol's Novel Anti-Fibrotic Mechanism of Action
Jan 19, 2021
Galmed Hosting KOL Symposium and Pipeline Update
Dec 17, 2020
Galmed to add Open Label Part to ARMOR Study; First Read-out Expected in Q4 2021
Nov 12, 2020
Galmed Pharmaceuticals Reports Third Quarter 2020 Financial Results
Nov 05, 2020
Galmed Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Business Update on Thursday November 12
Sep 10, 2020
Galmed and Gannex Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)
Sep 09, 2020
Gannex and Galmed Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta Agonist)
Aug 06, 2020
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results